Overview

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

Status:
Terminated
Trial end date:
2010-05-25
Target enrollment:
Participant gender:
Summary
To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Citric Acid
Sildenafil Citrate
Sodium Citrate